Flubromazolam’s purpose in clinical trials is limited as a consequence of its classification as being a designer drug. Having said that, its effects have already been reversed through the benzodiazepine antagonist flumazenil in pharmacokinetic scientific studies, giving insights into its scientific implications and crisis administration of overd